• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

悬浮 Vero 细胞批培养中甲型 H1N1 流感病毒的生产的统计优化。

Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero).

机构信息

Zelltek S.A., Parque Tecnológico Litoral Centro, Paraje El Pozo, RN 168 (S3000) Santa Fe, Pcia. Santa Fe, Argentina.

出版信息

Vaccine. 2011 Sep 22;29(41):7212-7. doi: 10.1016/j.vaccine.2011.07.016. Epub 2011 Jul 12.

DOI:10.1016/j.vaccine.2011.07.016
PMID:21756959
Abstract

Efficient vaccine production requires the growth of large quantities of virus produced with high yield from a safe host system. Human influenza vaccines are produced in embryonated chicken eggs. However, over the last decade many efforts have allowed the establishment of cell culture-derived vaccines. We generated a Vero cell line adapted to grow in suspension (sVero) in a serum-free medium and evaluated it for its potential as host cell for influenza vaccine production. Initially we studied the capacity of sVero cells to grow in the presence of incremental concentrations of trypsin. In comparison with adherent Vero cells (aVero), we found that sVero cells maintain their growth kinetics even with a three-fold increase in trypsin concentration. The influence of the conditions of infection on the yield of H1N1 produced in serum-free suspension cultures of sVero cells was investigated by a 2(2) full factorial experiment with center point. Each experiment tested the influence of the multiplicity of infection (m.o.i.) and trypsin concentration, on production yields at two levels, in four possible combinations of levels and conditions, plus a further combination in which each condition was set in the middle of its extreme levels. On the basis of software analysis, a combination of m.o.i. of 0.0066TCID(50%)/cell and trypsin concentration of 5μg/1.0×10(6) cells with a desirability of 0.737 was selected as the optimized condition for H1N1 production in sVero cells. Our results show the importance of proper selection of infection conditions for H1N1 production on sVero cells in serum-free medium.

摘要

高效疫苗生产需要从安全的宿主系统中大量生产高产量的病毒。人用流感疫苗是在鸡胚中生产的。然而,在过去的十年中,许多努力已经允许建立细胞培养衍生的疫苗。我们生成了一种适应在无血清培养基中悬浮生长的 Vero 细胞系(sVero),并评估了其作为流感疫苗生产宿主细胞的潜力。最初,我们研究了 sVero 细胞在递增浓度的胰蛋白酶存在下生长的能力。与贴壁 Vero 细胞(aVero)相比,我们发现 sVero 细胞即使在胰蛋白酶浓度增加三倍的情况下也能保持其生长动力学。通过 2(2)完全析因实验和中心点,研究了感染条件对无血清悬浮培养 sVero 细胞中产生的 H1N1 的产量的影响。每个实验测试了感染复数(m.o.i.)和胰蛋白酶浓度对生产产量的影响,在四个可能的水平组合和条件下进行了两种水平的测试,另外还进行了一个组合,其中每个条件都设置在其极端水平的中间。基于软件分析,选择 m.o.i.为 0.0066TCID(50%)/细胞和胰蛋白酶浓度为 5μg/1.0×10(6)细胞的组合,其理想性为 0.737,作为在无血清培养基中生产 sVero 细胞中 H1N1 的优化条件。我们的结果表明,对于在无血清培养基中生产 sVero 细胞中的 H1N1,适当选择感染条件非常重要。

相似文献

1
Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero).悬浮 Vero 细胞批培养中甲型 H1N1 流感病毒的生产的统计优化。
Vaccine. 2011 Sep 22;29(41):7212-7. doi: 10.1016/j.vaccine.2011.07.016. Epub 2011 Jul 12.
2
Continuous cell lines as a production system for influenza vaccines.连续细胞系作为流感疫苗的生产系统。
Expert Rev Vaccines. 2009 Dec;8(12):1681-92. doi: 10.1586/erv.09.128.
3
Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.在完全一次性平台工艺中生产细胞培养(MDCK)衍生的减毒活流感疫苗(LAIV)。
Biotechnol Bioeng. 2010 Aug 15;106(6):906-17. doi: 10.1002/bit.22753.
4
[Development of a novel influenza vaccine derived from a continuous cell line].[一种源自连续细胞系的新型流感疫苗的研发]
ALTEX. 2001;18(1):50-4.
5
Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.Vero 细胞培养衍生流感疫苗:疫苗生产的新视野。
Expert Rev Vaccines. 2012 May;11(5):587-94. doi: 10.1586/erv.12.24.
6
Downstream processing of Vero cell-derived human influenza A virus (H1N1) grown in serum-free medium.无血清培养基中培养的vero 细胞来源的人甲型流感病毒(h1n1)的下游处理。
J Chromatogr A. 2011 Aug 5;1218(31):5279-85. doi: 10.1016/j.chroma.2011.06.043. Epub 2011 Jun 17.
7
Serum-Free Suspension Culture of MDCK Cells for Production of Influenza H1N1 Vaccines.用于生产甲型H1N1流感疫苗的MDCK细胞无血清悬浮培养
PLoS One. 2015 Nov 5;10(11):e0141686. doi: 10.1371/journal.pone.0141686. eCollection 2015.
8
A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.一种新型的源自哺乳动物细胞(Vero细胞)的流感病毒疫苗:研发、特性鉴定及工业化规模生产。
Wien Klin Wochenschr. 1999 Mar 12;111(5):207-14.
9
Development of a Vero cell-derived influenza whole virus vaccine.一种源自Vero细胞的流感全病毒疫苗的研发。
Dev Biol Stand. 1999;98:101-10; discussion 111.
10
Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture.在大规模微载体培养中无血清流感病毒生产,避免洗涤步骤和培养基更换。
Vaccine. 2006 Apr 12;24(16):3261-72. doi: 10.1016/j.vaccine.2006.01.019. Epub 2006 Jan 19.

引用本文的文献

1
Multiscale modeling of influenza A virus replication in cell cultures predicts infection dynamics for highly different infection conditions.细胞培养中流感 A 病毒复制的多尺度建模预测了高度不同感染条件下的感染动力学。
PLoS Comput Biol. 2019 Feb 19;15(2):e1006819. doi: 10.1371/journal.pcbi.1006819. eCollection 2019 Feb.